Rock Springs Capital Management LP Cuts Stock Position in Compass Therapeutics, Inc. $CMPX

Rock Springs Capital Management LP cut its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 15.8% in the first quarter, HoldingsChannel.com reports. The fund owned 3,305,308 shares of the company’s stock after selling 621,894 shares during the period. Rock Springs Capital Management LP’s holdings in Compass Therapeutics were worth $17,485,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CMPX. Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $32,000. Russell Investments Group Ltd. raised its position in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Xponance LLC purchased a new position in Compass Therapeutics in the 4th quarter valued at about $55,000. CIBC Bancorp USA Inc. acquired a new stake in Compass Therapeutics in the 3rd quarter worth about $37,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Compass Therapeutics by 2,572.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock worth $58,000 after buying an additional 10,625 shares during the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

CMPX stock opened at $2.08 on Tuesday. The business has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $4.08. The firm has a market capitalization of $374.59 million, a PE ratio of -5.07 and a beta of 0.90. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, equities research analysts expect that Compass Therapeutics, Inc. will post -0.42 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research report on Monday, April 27th. Canaccord Genuity Group dropped their price target on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Raymond James Financial downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. Stifel Nicolaus set a $6.00 target price on shares of Compass Therapeutics in a research note on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and an average price target of $12.25.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.